U.S. Professional Services Stock News

Event driven interest in NewAmsterdam Pharma NewAmsterdam Pharma (NasdaqGM:NAMS) is back on investors’ radar after an investor letter highlighted optimism around trial outcomes for its CETP inhibitor obicetrapib, supported by new data presentations at the ACC.26 cardiology conference. See our latest analysis for NewAmsterdam Pharma. NewAmsterdam Pharma’s recent presentations around obicetrapib, combined with the investor letter, come as the share price sits at US$32.99, with strong recent...

Georgia homeowners filed an arbitration complaint alleging D.R. Horton (NYSE:DHI) sold new homes with defective PEX plumbing that led to leaks and water damage. The filing claims D.R. Horton repaired some affected homes but did not alert all potentially impacted owners. Similar plumbing related complaints and legal actions are reported in multiple states, suggesting the issue may extend beyond Georgia. D.R. Horton is a major U.S. homebuilder focused on constructing and selling new...

ICON (ICLR) is back in focus after first quarter results showed earnings per share of $3.29, slightly below analyst expectations, while revenue of $2.01b aligned with consensus estimates. See our latest analysis for ICON. The latest 1 day share price return of 2.49% and 7 day gain of 11.86% come after a much steeper 90 day share price decline of 42.21%, leaving 1 year total shareholder return at a 25.72% loss. This indicates that recent momentum has been more positive despite a weaker longer...

Recent gains in Bicara Therapeutics (BCAX) stock have come alongside a series of fresh analyst updates, earnings results and clinical progress headlines that have sharpened attention on the company’s development pipeline. See our latest analysis for Bicara Therapeutics. The recent analyst upgrades and clinical updates have come alongside a clear build in momentum, with a 30 day share price return of 16.24% and a 1 year total shareholder return of 103.12% at a latest share price of $21.47. If...

Zenas BioPharma (ZBIO) has just raised fresh capital through a twin financing, completing a US$100 million follow on common stock offering at US$20 per share and a US$200 million 2.50% convertible notes issue due 2032. See our latest analysis for Zenas BioPharma. The fresh capital raise comes after a mixed stretch for the stock, with a 29.2% 90 day share price return contrasting with a 15.1% 1 month share price decline, while the 1 year total shareholder return of 178.3% points to strong...

Upwork (NasdaqGS:UPWK) is rolling out new AI driven features on its freelance platform, including its assistant Uma and expanded workforce management tools. The company is extending these capabilities across its marketplace to support both businesses and freelancers who rely on remote and project based work. The updates are part of an ongoing effort to integrate AI into talent discovery, project scoping, and ongoing engagement on the platform. For investors tracking online talent platforms,...

In March 2026, Worthington Enterprises, Inc. reported higher year-over-year third-quarter and nine-month sales and net income, continued its share repurchases, and its Board declared a US$0.19 per-share quarterly dividend payable on June 29, 2026. Together, the earnings growth, ongoing buybacks that have retired more than two-fifths of shares since 2014, and the uninterrupted dividend record since 1968 highlight the company’s long-running focus on returning cash to shareholders. Next, we’ll...

In early April 2026, Ferguson Enterprises drew fresh analyst support as research firms highlighted its robust fiscal guidance and growing exposure to non-residential construction, especially for data center-related projects. This renewed focus on Ferguson’s role in supplying critical infrastructure for data centers underscores how shifting technology needs are influencing demand in its core end markets. Next, we’ll examine how this increased emphasis on data center-driven non-residential...

Ryman Hospitality Properties recently announced a cash dividend of US$1.20 per share with an ex-dividend date of March 31, 2026, highlighting its focus on returning capital to shareholders. This payout, backed by solid net income and disciplined expense control, reinforces Ryman’s appeal to income-focused investors who prioritize dividend sustainability. We’ll now explore how this emphasis on a sizeable, seemingly sustainable cash dividend shapes Ryman’s broader investment narrative and...

AGCO recently reported past Q4 2025 results with earnings per share of US$2.17 on revenue of US$2.92 billion, exceeding analyst expectations on both metrics. A simultaneous promotion of Jena Holtberg-Benge to Chief Digital and Information Officer highlights AGCO’s push to embed AI and digital capabilities more deeply into its farm equipment portfolio. We’ll now examine how AGCO’s earnings beat and AI-focused leadership change influence the company’s investment narrative and long-term...

RCM Technologies (RCMT) has wrapped up FY 2025 with fourth quarter revenue of US$86.5 million, basic EPS of US$0.80 and net income of US$6.1 million. The trailing twelve months show revenue of US$319.4 million, EPS of US$2.19 and net income of US$16.3 million, with earnings growth of 22.4% over the past year. Over recent periods the company has seen revenue move from US$278.4 million to US$319.4 million on a trailing basis, alongside EPS shifting from US$1.72 to US$2.19. This ties into a net...

Dole recently faced an analyst downgrade from Deutsche Bank to Hold after its latest quarter showed revenue growth but weaker-than-expected profitability metrics, highlighting pressure on margins despite stronger sales. Next, we’ll examine how the earnings-related margin pressure highlighted by Deutsche Bank affects Dole’s existing investment narrative and risk-reward balance.

Why ivonescimab data at ELCC 2026 matters for Summit Therapeutics (SMMT) Summit Therapeutics (SMMT) drew investor attention after presenting new clinical data for its investigational bispecific antibody, ivonescimab, at the 2026 European Lung Cancer Congress in Copenhagen. The update covered multiple Phase III trials in non small cell lung cancer and colorectal cancer, providing new information on the progress of Summit’s late stage pipeline and how that progress may relate to the current...

AXT (NasdaqGS:AXTI) is expanding indium phosphide wafer manufacturing capacity, with a plan to roughly double output for AI data center customers. The company is responding to a growing order backlog linked to AI infrastructure build outs. Management is pursuing this capacity increase without very large new capital expenditure, following prior equity offerings that raised dilution concerns for some investors. The expansion comes as AXT continues to operate under export related constraints...

Compañía de Minas BuenaventuraA (NYSE:BVN) announced a significant semi-annual dividend increase. The new dividend payment has been set for shareholders, marking a material update to the company’s capital returns policy. This dividend decision follows a period where recent commentary on NYSE:BVN focused mainly on share price and valuation. Compañía de Minas BuenaventuraA is a Peru based precious metals producer. Its fortunes sit closely with gold and silver markets, funding conditions for...

In recent months, Soleno Therapeutics has faced multiple securities class action lawsuits alleging that the company and certain executives failed to disclose material safety concerns and data integrity issues tied to the Phase 3 program for its Prader‑Willi syndrome drug DCCR, marketed as VYKAT XR. These legal challenges, centered on claims of undisclosed risks such as fluid retention, diabetes‑related markers, and high discontinuation rates, have intensified scrutiny of VYKAT XR’s clinical...

Radware recently authorized a new US$80.00 million share repurchase plan while completing its acquisition of API security testing firm Pynt and doubling its global cloud security mitigation capacity to 30 Tbps. Together, these moves highlight Radware’s intention to return capital to shareholders while deepening its capabilities in high-demand API and cloud security. We’ll now examine how Radware’s new share repurchase program may influence the company’s broader investment narrative and...

Repligen (RGEN) is back on investors’ radar after recent share price moves, with the stock closing at US$117.78. That puts fresh attention on how its bioprocessing business and current valuation line up. See our latest analysis for Repligen. The recent 7 day share price return of 6.96% comes after a 90 day share price decline of 28.34% and a 1 year total shareholder return of 5.22%. This suggests that short term momentum is improving, while longer term returns remain mixed. If this kind of...

In recent days, Assured Guaranty director Francisco Borges sold 123,750 shares of the company, a transaction worth nearly US$9.93 million, marking a large reduction in his personal stake. This insider sale comes as Assured Guaranty balances strong profitability and a solid balance sheet with pressures from lower-yield AA business and its Assured Life Re annuity reinsurance expansion. We’ll now examine how Borges’ sizable insider sale could influence Assured Guaranty’s investment narrative,...

In recent days, Equity LifeStyle Properties attracted fresh analyst attention as Mizuho initiated coverage with an outperform rating, while BofA Securities and BMO Capital reaffirmed their positive views on the residential REIT. Analysts emphasized the company’s comparatively strong same-store revenue and core funds from operations performance, alongside resilient manufactured home and annual RV revenue streams within the broader residential REIT sector. Next, we’ll examine how this cluster...

Recently, analysts at Sidoti cut their Q1 2026 earnings-per-share forecast for HNI Corporation to $0.31, following earlier downgrades after a Q4 2025 earnings miss in its office furniture and hearth businesses. This shift in expectations highlights growing concern that industry headwinds and execution risks may weigh more heavily on HNI’s near-term profitability than previously thought. We’ll now examine how Sidoti’s reduced Q1 2026 EPS forecast may affect HNI’s earlier investment narrative...

Noble Financial analyst M. Reichman recently cut his Q2 2026 earnings-per-unit estimate for Alliance Resource Partners from $0.65 to $0.51, signaling a softer near-term profit outlook for the coal producer. This revision highlights how quickly analyst sentiment can adjust to evolving expectations for Alliance’s coal and royalty businesses, even amid previously supportive industry conditions. We’ll explore how this reduced Q2 2026 earnings estimate may affect Alliance Resource Partners’...

AI data centers, stubborn energy costs, and heightened geopolitical risk are all pushing reliable, carbon free power to the forefront of investment thinking. Nuclear sits at the center of that discussion, with governments, utilities, and large corporates all searching for 24/7 electricity that does not depend on weather or imported fossil fuels. Our Nuclear Renaissance screener is built to help you focus on listed companies most closely aligned with this long term trend. In this article, you...

Viking Holdings (VIK) is back in focus after reporting fourth quarter 2025 earnings that topped expectations, supported by higher Capacity Passenger Cruise Days, stronger occupancy, and revenue per passenger, alongside ongoing fleet expansion across rivers and oceans. See our latest analysis for Viking Holdings. The better than expected quarter appears to sit behind Viking Holdings' recent momentum, with a 9.1% 7 day share price return and a very large 1 year total shareholder return, even...